Amit Mehta, M.B.B.S., M.B.A.

Dr. Mehta is a hematology specialist with a focused clinical and research interest in lymphoma and advanced cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy. His work centers on advancing innovative, non-chemotherapy treatment strategies that harness the immune system to improve outcomes for patients with hematologic malignancies.

Dr. Mehta is deeply engaged in exploring next-generation immunotherapy approaches for lymphoma, including cellular therapies, immune-modulating agents, and targeted biologics. His emphasis lies in identifying and integrating novel treatment paradigms that reduce reliance on conventional cytotoxic chemotherapy while enhancing efficacy, durability of response, and quality of life. With a strong commitment to translational medicine, Dr. Mehta is interested in bridging cutting-edge research and clinical practice—bringing emerging therapies from bench to bedside. His areas of focus include CAR-T optimization, resistance mechanisms, toxicity management, and expanding access to cellular therapies across diverse patient populations.

Dr. Mehta brings a systems-level perspective to cancer care, emphasizing innovation, efficiency, and scalable models for delivering complex therapies such as CAR-T. He collaborates across multidisciplinary teams to drive forward clinical excellence and contribute to the evolving landscape of cancer treatment.